Back to news

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire•20/11/2026•16:05 ET
1

Key Highlights

  • ➤18,000 restricted shares granted to one new non-executive employee
  • ➤Restricted stock vests over three years, subject to continued employment
  • ➤Inducement grants issued under Nasdaq Rule 5635(c)(4) and 2024 Inducement Plan
  • ➤Company cites recurring losses, negative operating cash flows, and going-concern doubt
  • ➤Voluntary U.S. recall of CGuard Prime 135 cm delivery system remains a risk

MIAMI, Nov. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to one new non-executive employee in the aggregate amount of 18,000 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of November 19, 2026, as an inducement material to the non-executive employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grants were granted under the InspireMD’s 2024 Inducement Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in